A5085812944- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Molecular Biology Techniques and Applications
- Bladder and Urothelial Cancer Treatments
- Epigenetics and DNA Methylation
- Urologic and reproductive health conditions
- Bioinformatics and Genomic Networks
- Radiomics and Machine Learning in Medical Imaging
- Computational Drug Discovery Methods
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Ureteral procedures and complications
- Renal cell carcinoma treatment
- Urinary Bladder and Prostate Research
- Lung Cancer Treatments and Mutations
- Pelvic floor disorders treatments
- Hormonal and reproductive studies
- Ferroptosis and cancer prognosis
- MRI in cancer diagnosis
- Renal and Vascular Pathologies
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Pediatric Urology and Nephrology Studies
Columbia University Irving Medical Center
2014-2023
New York Proton Center
2012-2020
Winthrop-University Hospital
2017
New York Hospital Queens
2012-2016
NewYork–Presbyterian Hospital
2012-2016
Columbia University
2012-2013
Morgan Stanley Children's Hospital
2012-2013
Memorial Sloan Kettering Cancer Center
2008-2009
BG University Hospital Bergmannsheil Bochum
2009
Ruhr University Bochum
2009
Reverse transcription-PCR (RT-PCR) assays have been used for analysis of circulating tumor cells (CTCs), but their clinical value has yet to be established. We assessed men with localized prostate cancer or castration-refractory (CRPC) CTCs via real-time RT-PCR KLK3 [kallikrein-related peptidase 3; i.e., prostate-specific antigen (PSA)] and KLK2 mRNAs. also the association disease characteristics survival.KLK3, KLK2, PSCA (prostate stem cell antigen) mRNAs were measured by standardized,...
A three-gene panel derived from mechanistic models of cell senescence predicts outcome low Gleason score prostate tumors.
Abstract Predicting in vivo response to antineoplastics remains an elusive challenge. We performed a first-of-kind evaluation of two transcriptome-based precision cancer medicine methodologies predict tumor sensitivity comprehensive repertoire clinically relevant oncology drugs, whose mechanism action we experimentally assessed cognate cell lines. enrolled patients with histologically distinct, poor-prognosis malignancies who had progressed on multiple therapies, and developed low-passage,...
Purpose: Focal cryoablation targets unilateral disease, sparing healthy tissue and the ipsilateral neurovascular bundle. Given half prostate is spared, proper patient selection imperative to optimize outcomes. We report focal cryotherapy outcome data evaluate accuracy of 2007 Task Force criteria at predicting disease recurrence. Materials Methods: This a retrospective chart review from single academic institution. Inclusion criterion having cancer treated with primary hemicryoablation....
Introduction: Micropapillary bladder cancer (MPBC) is a variant histology of urothelial carcinoma (UC) that associated with poor outcomes however given its rarity, little known outside institutional reports. We sought to use population-level database assess survival in patients treated surgery, radiation therapy and/or chemotherapy. Materials and Methods: The National Cancer Database (NCDB) was queried for all cases MPBC UC using International Classification Disease-O-3 morphologic codes...
Mitochondria provide the first line of defense against tumor-promoting effects oxidative stress. Here we show that prostate-specific homeoprotein NKX3.1 suppresses prostate cancer initiation by protecting mitochondria from Integrating analyses genetically engineered mouse models, human cells, and organotypic cultures, find that, in response to stress, is imported via chaperone protein HSPA9, where it regulates transcription mitochondrial-encoded electron transport chain (ETC) genes, thereby...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jan 2004Comparison Accuracy Between the Partin Tables Of 1997 and 2001 to Predict Final Pathological Stage in Clinically Localized Prostate Cancer HERBERT AUGUSTIN, THILO EGGERT, SVEN WENSKE, PIERRE I. KARAKIEWICZ, JÜRI PALISAAR, FEDOR DAGHOFER, HARTWIG HULAND, MARKUS GRAEFEN AUGUSTINHERBERT AUGUSTIN , EGGERTTHILO EGGERT WENSKESVEN WENSKE KARAKIEWICZPIERRE KARAKIEWICZ PALISAARJÜRI PALISAAR DAGHOFERFEDOR DAGHOFER HULANDHARTWIG...
Multiple phase I-II clinical trials have reported on the efficacy and safety of prostate stereotactic body radiotherapy (SBRT) for treatment cancer. However, few outcomes SBRT using periprostatic hydrogel spacer (SpaceOAR; Augmenix). Herein, we report from our institutional experience with SpaceOAR placement. Fifty men low- or intermediate-risk cancer treated at a single institution linear accelerator-based to 3625 cGy in 5 fractions, without androgen deprivation therapy (ADT) were included....
To assess the peri- and postoperative outcome of patients treated with open radical retropubic prostatectomy (RRP) for prostate cancer who had previously undergone transurethral resection (TURP).Prospectively collected data from a consecutive series 1760 RRP between July 2003 June 2007 at our institution were used to retrospectively match 62 cases (with previous TURP) same number controls (without TURP). Matching variables patient age, body mass index, volume, preoperative total...
Worldwide, uroflowmetry without simultaneous electromyography is often the only testing performed during initial assessment of children with lower urinary tract symptoms. Various alterations in uroflow pattern are thought to indicate particular types conditions, specifically staccato indicating dysfunctional voiding and intermittent/fractionated detrusor underactivity. We determined how reliable alone as a surrogate for simultaneously measured pelvic floor activity voiding, well interrupted...
We aim to test the hypothesis that neurovascular bundle (NVB) displacement by rectal hydrogel spacer combined with NVB delineation as an organ at risk (OAR) is a feasible method for NVB-sparing stereotactic body radiotherapy.Thirty-five men low- and intermediate-risk prostate cancer who underwent placement pre-, post-spacer MRI studies were treated SBRT (36.25 Gy in five fractions). A radiologist contoured on both pre- T2W sequences then registered CT simulation scan radiation treatment...
The accumulation of data through a prospective, multicenter coordinated registry network is practical way to gather real world evidence on the performance novel prostate ablation technologies. Urological oncologists, targeted biopsy experts, industry representatives and FDA (Food Drug Administration) convened discuss role, feasibility important elements assess new existing technologies.A multiround Delphi consensus approach was performed which included opinion 15 expert urologists,...